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Abstract
Background: To perform a systematic review about the effect of using clinical pathways on length of stay (LOS),
hospital costs and patient outcomes. To provide a framework for local healthcare organisations considering the
effectiveness of clinical pathways as a patient management strategy.
Methods: As participants, we considered hospitalized children and adults of every age and indication whose
treatment involved the management strategy "clinical pathways". We include only randomised controlled trials
(RCT) and controlled clinical trials (CCT), not restricted by language or country of publication. Single measures
of continuous and dichotomous study outcomes were extracted from each study. Separate analyses were done
in order to compare effects of clinical pathways on length of stay (LOS), hospital costs and patient outcomes. A
random effects meta-analysis was performed with untransformed and log transformed outcomes.
Results: In total 17 trials met inclusion criteria, representing 4,070 patients. The quality of the included studies
was moderate and studies reporting economic data can be described by a very limited scope of evaluation. In
general, the majority of studies reporting economic data (LOS and hospital costs) showed a positive impact. Out
of 16 reporting effects on LOS, 12 found significant shortening. Furthermore, in a subgroup-analysis, clinical
pathways for invasive procedures showed a stronger LOS reduction (weighted mean difference (WMD) -2.5 days
versus -0.8 days)).
There was no evidence of differences in readmission to hospitals or in-hospital complications. The overall Odds
Ratio (OR) for re-admission was 1.1 (95% CI: 0.57 to 2.08) and for in-hospital complications, the overall OR was
0.7 (95% CI: 0.49 to 1.0). Six studies examined costs, and four showed significantly lower costs for the pathway
group. However, heterogeneity between studies reporting on LOS and cost effects was substantial.
Conclusion: As a result of the relatively small number of studies meeting inclusion criteria, this evidence base is
not conclusive enough to provide a replicable framework for all pathway strategies. Considering the clinical areas
for implementation, clinical pathways seem to be effective especially for invasive care. When implementing clinical
pathways, the decision makers need to consider the benefits and costs under different circumstances (e.g. market
forces).
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Background
Clinical pathways represent a form of "cookbook medi-
cine" that many perceive as an appropriate tool that con-
tributes to quality management, cost-cutting and patient
satisfaction.
For the aim of this review, clinical pathways are defined as
complex interventions consisting of a number of compo-
nents based on the best available evidence and guidelines
for specific conditions [1]. A clinical pathway defines the
sequencing and timing of health interventions and should
be developed through the collaborative effort of physi-
cians, nurses, pharmacists, and other associated health
professionals [2]. Clinical pathways aim to minimize
delays and maximize resource utilization and quality of
care [1]. They are also referred to as "integrated care path-
ways", "critical pathways", "care plans", "care paths",
"care maps" and "care protocols".
The effectiveness of clinical pathways is under debate.
However, especially in the US, up to 80 percent of hospi-
tals already use clinical pathways for at least some indica-
tions [3]. A number of primary studies considered the
effectiveness of clinical pathways, but results are incon-
sistent and suffer from various biases [4-7]. Only one sys-
tematic review has been performed, specifically for stroke
patients [8]. Narrative reviews are more common, which
often rely on "expert opinions" [9-11].
We perform a systematic review and a random effects
meta-analysis to assess whether clinical pathways
improved the outcome measures "length of stay (LOS)",
"hospital costs" and "quality of care" when compared to
standard care. By performing a systematic review and
meta-analysis we are able to present the available evi-
dence in a substantiated and concise way, in order to pro-
vide a framework for local healthcare organisations
considering the effectiveness of clinical pathways.
Methods
We followed the methods of the Cochrane Collaboration
[12] with some modifications, mainly concerning presen-
tation of meta-analytic results.
Study selection criteria
As potential patient samples we considered hospitalized
children and adults of every age and indication, whose
treatment involved the management strategy "clinical
pathways". Given the problem that there are variations in
the terminology used in the current research [13], we
defined minimum "inclusion criteria" for meeting our
clinical pathway definition (see Table 1). Based on our
definition (see background), we developed a pre-speci-
fied, three operational pathway criteria as follows: 1)
multidisciplinary (two or multiple clinical professions
involved), 2) protocol or algorithm based (i.e. structured
care plan/treatment-protocol or algorithm) and finally, 3)
evidence based (pathway components were minimally
based on one RCT or best practice guidelines). Every path-
way characteristic could be met as (1) "yes" criterion; (2)
"not sure" because of poor reporting and the failure to
contact the principal author or (3) "criterion not met." If
one or more pathway criteria selected is not met, then we
excluded the study.
Please note, additional information relating to the
included studies that matched these requirements or dif-
fer from each other, are given in the results section of this
review.
The setting definition covered the whole range of services
offered by the clinical (out- and in-patient) as well as in
the in-patient rehabilitation sector. We only gathered
robust evidence and limited our study selection to ran-
domised controlled trials (RCT) and controlled clinical
trials (CCT) including methodological quality criteria
(please see "quality assessment and data analyses").
We considered every objective economic and patient out-
come for inclusion. We pre-defined (1) in-hospital com-
plications as a secondary disease or adverse medical
occurrence during hospitalization [14] and (2) we defined
re-hospitalization as a readmission within a specified fol-
low up period of an index admission.
Data sources and search strategy
We performed specialised searches of the Medline data-
base (1966–2006), Embase (1980–2006), Cinahl (1982–
2006), Global Health (1973–2006), and the specialised
Cochrane register (including NHS EED and HTA Data-
base; last update: 13.11.06), not restricted by language or
country. We used free text words (tw), medical subject
headings (MeSH terms -/-) or exploded MeSH terms for
our MEDLINE literature search. This controlled vocabu-
lary was adapted (as much as possible) to the indexation
(thesaurus) of all other databases included in this review.
We demonstrate our "clinical pathway search strategy"
with the MEDLINE inquiry (Table 2).
Furthermore, we employed citation tracking, which exam-
ines included studies and previous reviews and contacted
investigators to identify any study missed by the electronic
searches.
Quality assessment and data analysis
For quality of studies (see additional File 1), we adhered
to the Effective Organisation of Care Group (EPOC) mod-
ule[15] and defined three risk classes: Class I (low risk of
bias), Class II (moderate risk of bias) and Class III (high
risk of bias). Two reviewers independently assessed andBMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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Table 1: Pathway characteristics and quality outcome measures of studies included
Pathway Charac-
teristics
Quality Measure Pathway [n/N] Control [n/N]
Study-ID multi-
disciplinary
evidence-based protocol/
algorithm 
based
Counts and rates 
are presented in 
natural units and 
as percentages as 
far as reported
N = numer of 
participants n = 
number of 
events (%) = 
percentage
Invasive Care
Grines, CL X X X In-hospital 
complications
20/237 (8.4%) 20/234 (8.5%) N.S.
1998 Re-hospitalisation 
(6 months)
10/237 (4.2%) 9/234 (3.9%) N.S.
Swanson, CE X Not X Hospital mortality 2/38 (5.2%) 2/33 (6.1%) N.S.
1998 sure Mean Modified 
Barthel Index
92.8 85.6 (p < 0.05)
Dowsey, MM X X X In-hospital 
complications
10/92 (10.8%) 20/71 
(28.1%) (p < 0.05)
1999 Re-hospitalisation 
(3 months)
1/92 (1.1%) 0/71 (0%) N.S.
Choong, PF X X X In-hospital 
complications
10/55 (18.2%) 14/56 (25.0%) N.S.
2000 Re-hospitalisation 
(28 days)
2/55 (3.6%) 6/56 (10.7%) N.S.
Aizawa, T X X X In-hospital 
complications
1/32 (3.1%) 2/37 (5.4%) N.S.
2002 Re-hospitalisation 
(6 months)
1/32 (3.1%) 0/37 (0%) N.S.
Kiyama, T X X X In-hospital 
complications
3/47 (6.4%) 5/38 (13.2%) N.S.
2003
Hirao, M X X X In-hospital 
complications
19/53 (35.8%) 17/50 (34.0%) N.S.
2005 Re-hospitalisation 
(6 months)
0/53 (0%) 0/50 (0%)
Non-Invasive 
Care
Falconer, JA X Not X Mortality 
(12 months)
N.S. N.S.
1993 Sure Re-hospitalisation 
(12 months)
N.S. N.S.
Cognitive and 
functional scores 
(0–100)
N.S. N.S.
Patient satisfaction 7.7 (SD 2.6) 8.8 
(SD 1.7) (p < 0.05)
Gomez, MA X X X Complete and 
graded exercise 
test
44/50 (88.0%) 15/50 (30.0%)
1996
Roberts, RR X X X Hospitalised 
patients as %
(45.1%) (100%)
1997 Re-hospitalisation 
(8 weeks)
5/82 (6.1%) 4/83 (4.8%) N.S.
Johnson, KB 2000 X X X Unscheduled clinic 
visits; no hospital 
re-admission 
(2 weeks)
0/55 (0%) 2/55 (3.6%)
Kollef, HM X X X In-hospital 
complications
9/239 (3.8%) 13/250 (5.2%) N.S.
2000 Hospital mortality 5/239 (2.1%) 8/250 (3.2%) N.S.BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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Marrie, TJ 2000 X X X Absolute difference 
in rates (ARR) 
between pathway 
and control
1-sided 95% CI 
upper limit:
In-hospital 
complications
(0.6%) (4.6%) N.S.
Re-hospitalisation 
(6 weeks)
(0.7%) (3.6%) N.S.
Mortality (6 weeks) (-0.1%) (2.5%) N.S.
Sulch, D X X X Median Barthel 
Index Score 
(26 weeks)
17 17 N.S.
1999 Mortality 
(26 weeks)
10/76 (13.2%) 6/76 (7.9%) N.S.
Kim, MH X X X Complications until 
follow-up (27 days)
1/9 (11.1%) 1/9 (11.1%) N.S.
2002 Re-hospitalisation 
(27 days)
2/9 (22.2%) 0/9 (0%) N.S.
Chen, SH 2004 X X X Emergency room 
usage (not 
comparable with 
in-hospital 
complications)
3/20 (15.0%) 13/22 
(59.1%) (p < 0.05)
Re-hospitalisation 
(3 months)
N.S. N.S.
Usui, K 2004 X X X Not reported
Legend: Every pathway characteristic could be met as (1) "yes" criterion; (2) "not sure" because of poor reporting and the failure to contact the 
principal author or (3) "criterion not met." If one or more pathway criteria selected is/are not met, then we excluded the study. Due to poor 
reporting some quality measures are presented only as percentages or mean scores with or without associated standard deviations (SD). Some 
quality measures were only reported as statistical significant (i.e. p < 0.05) or not significant (N.S.) and any other data were missing.
Table 1: Pathway characteristics and quality outcome measures of studies included (Continued)
Table 2: Clinical pathway search strategy Ovid Medline: 1966 to November Week 2 2006
1. Critical Pathways/
2. (clinical path$ or critical path$ or care path$ or care map$).tw.
3. exp Guidelines/
4. Health Planning Guidelines/
5. Guideline Adherence/
6. (guideline? adj2 introduc$ or issu$ or impact or effect? or disseminat$ or distribut$)).tw.
7. nursing protocol$.tw.
8. (professional standard$ or professional protocol or professional care map).tw.
9. (practice guidelin$ or practice protocol$ or clinical practice guideline$).tw.
10. guideline.pt.
11. or/1–10
12. exp Hospitalization/
13. (in-patient or hospitalized or hospitalised or hospitalisation or hospitalization).tw.
14. exp Outpatient Clinics, Hospital/
15. in-hospital.tw.
16. exp Hospital Units/
17. (Patient Admission or patient readmission or patient readmission or discharge).tw.
18. or/12–17
19. 11 and 18
20. randomized controlled trial.pt.
21. controlled clinical trial.pt.
22. intervention studies/
23. experiment$.tw.
24. pre test or pretest or (posttest or post test)).tw.
25. random allocation/
26. or/20–25
27. 18 and 26BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
Page 5 of 15
(page number not for citation purposes)
abstracted data, on the intervention criteria, study charac-
teristics and methodological quality. Any disagreement
was discussed with a third reviewer. Studies with a high
risk of bias were excluded from the review after documen-
tation. If a primary study did not provide information
about the standard deviation, we used the approximative
or direct algebraic connection between the stated confi-
dence intervals, or p-values, and the standard deviation
and calculated the inverse transformation to the individ-
ual or pooled standard deviation [12]. Prior to the actual
statistical pooling of the singular effects, an adjustment of
the data regarding costs due to inflation and price adjust-
ment (OECD Health Care Price Index) was carried out
[16]. We chose the US Dollar (USD) as the basic currency.
The year 2000 was chosen as a representative year for
inflation and price adjustments or exchange rates.
We used Review Manager (RevMan) of the Cochrane Col-
laboration to calculate a pooled effect estimate, called
weighted mean difference (WMD) [17]. We used a ran-
dom effects model since this model estimates the effect
with consideration to the variance between studies, rather
than ignoring heterogeneity by employing a fixed effect
model. The effect sizes were generated using a model fit-
ting inverse variance weights [17].
Heterogeneity and meta-analysis
Despite the expected clinical heterogeneity (clinical varia-
bility of the included pathway interventions) within the
review, it is important to assess the comparability of the
results from individual studies. A useful statistic for quan-
tifying inconsistency is I2 = [(Q df)/Q] × 100%, where Q
is the chi-squared statistic and df is its degrees of freedom
[12]. This quantifies the total variance explained by the
heterogeneity as a percentage. We considered an overall
test-value greater than 60% to serve as evidence of sub-
stantial heterogeneity of a magnitude were statistical
pooling is not appropriate.
Sensitivity analysis
In a sensitivity analysis, both fixed effects and random
effects models were employed to determine the causes of
heterogeneity and test the confidence that can be placed
in both estimates. Only robust estimations of the pooled
effects with similar results in fixed effects and random
effects models are included in the meta-analysis and dis-
cussed. Furthermore, sensitivity analyses were performed
to test whether the effect size varied by the countries
where the study was carried out (adjusting for market
forces) and the year of publication, adjusting for temporal
trends.
Subgroup analysis
We decided previously to perform a subgroup analysis of
invasive versus non-invasive clinical pathways, where-
upon the distinction between invasive or non-invasive
interventions refers to the nature of patient management
guided by clinical pathways (i.e. clinical pathways for gas-
trectomy; transurethral resection of the prostate; hip and
knee arthroplasty; percutaneous transluminal coronary
angioplasty; etc. versus clinical pathways for asthma care;
stroke; pneumonia; etc.). According to theories on health
economics, invasive procedures can be standardized more
easily than treatment strategies in conservative sectors due
to the lower treatment variance [18].
Assessing publication bias
We used a funnel plot analysis to assess publication bias,
i.e. the bias caused by a lower likelihood of publication
for non-significant studies. The funnel plot is a scatter-
plot with the x-axis representing the effects estimated from
the primary studies, and the y-axis representing a measure
of the sample size in each study (SE; standard error of the
mean) [19]. If publication bias is absent, the diagram
shows an inverted symmetrical funnel.
However, given that publication bias poses a threat to the
validity of this meta-analysis and the graphical method is
subjective in nature, we also applied a statistical approach,
often called fail-safe N test.
This test provides an estimate of the number of unpub-
lished or in this context called file-draw studies (Nfs) hav-
ing an average of no effect that is necessary in the analysis
for reducing the pooled effect size from significant to non-
significant [20]. Using a critical d level (d crit) of -0.20, the
estimate of unpublished studies was calculated with
Nfs = (Ntotal (mean d - d crit))/d crit;
where Ntotal is the total number of studies included in the
Meta-Analysis and d is the overall pooled effect (WMD).
Secondary analyses
The distribution of the length of stay is limited down-
wards in a natural way (because of the minimum value is
always 0), whereas upwards the values can scatter signifi-
cantly. According to logarithmic transformation, values
with this characteristic can have an approximately normal
distribution [21]. In the additional File 2 we detailed the
formulas used for log transformation. Data analyses were
performed using SPSS version 15.0 [22].
Results
Search strategy and intervention characteristics
The specialised search strategy led to the initial selection
of 2,386 studies, whereas only 17 matched our methodi-
cal requirements (see Figure 1 &2). For the first stage of
the study assessment, we scanned all of the 2,386 titles
and abstracts for inclusion, the remaining 256 possiblyBMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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relevant studies were retrieved as full text articles. Based
on the full text assessment, we excluded 190 studies out of
256 because they failed to meet our pathway definition.
The majority of the excluded studies failed to meet the
multidisciplinary pathway criterion, i.e. it was a therapy
guideline issued by a medical association or it was a uni-
professional nursing care plan. Others did not meet the
"algorithm or protocol based" criterion because there was
no structure and detailed care plan. For example a poster
with issued guidelines was posted in the Emergency
Department.
Evidence for meeting the minimal criterion "pathway con-
tent is minimally based on one RCT" was reported in 15
studies out of 17, which were included in the review. The
study from Falconer et al. and Swanson at al. met the evi-
dence criterion, "not sure" because we failed in contacting
the principal investigators [23,24].
Intervention characteristics
The reported pathway strategies can be described as com-
plex pathway interventions versus a "non-intervention"
control group or often poorly, described as "usual or tra-
ditional care" group. Most of the experimental interven-
tions were combined with other types of interventions
like audit and feedback, educational meetings, and
reminders. For 8 out of the 17 (47%) included studies, it
was clear that the structured care plan was combined with
a "clinical diagnostic or assessment protocol"[23,25-31].
The evidence base for two (12%) pathway interventions
was "not sure," whereas the remaining 15 interventions
were minimally based on one randomized study or good
evidence. The reported purpose of the pathway strategies
was appropriate management or cost containment.
The hospital setting was in two studies a multi-center
study comprising a range of hospitals included in the
investigation [26,30]. From the 15 remaining single
center studies, 8 studies (53%) were carried out in a uni-
versity (teaching) hospital setting [24,27-29,32-35] and 7
studies (46%) in a non-university hospital setting
[23,25,31,36-39].
Details of the intervention characteristics are given in
Table 3.
Quality assessment
To summarize, we examined the design and study quality
of 66 studies, excluding 49 out of the 66 studies because
of the high risk of bias (see trail flow, Figure 1). Character-
istics (reason for exclusion: see additional File 3) of the 49
excluded studies (references to excluded studies: see addi-
tional File 4) are given in detail.
Identification of relevant studies/trail flow Figure 1
Identification of relevant studies/trail flow. [see attached file 1] (PDF Format).
2386
4 CCTs
2130
256
190
66
49
17
13 RCTs
Product of search strategy
Excluded and not downloaded
Possibly relevant
Excluded as pathway definition not 
met (intervention not comparable)
Considering for inclusion
Excluded for listed reason
(quality criteria not met)
Studies included in review
2386
256
66
2386
256
17
66
2386
256
4 CCTs
17
66
2386
256
13 RCTs 4 CCTs
17
66
2386
256BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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The patient was randomized to the experimental or con-
trol group in 12 out of 13 (92%) RCTs. The randomiza-
tion process was clear in all such studies and justified by
the authors. Referring to the individually randomized and
single-center studies, the assessment of protection against
contamination of the control professionals remained
unclear due to poor reporting. None of the investigators
reported protection against contamination (communica-
tion between experimental and control professionals) and
it is possible that control subjects received the interven-
tion. Only the investigation from Marie et al. used a
robust cluster randomized design, with 19 hospitals as
unit of allocation [30]. To avoid "unit of analysis error,"
we conducted the meta-analysis at the same level as the
allocation (19 cluster-hospitals = 19 patients).
Poor reporting also lead to difficulties in determining the
assessment of the power calculations. For instance, sam-
ple-size calculation was unclear for over 60% of the
included studies; hence the study sample may not have
been sufficiently large. Another problem, due to poor
reporting was the selection of comparators. The choice of
the comparator (i.e. the control and intervention units
were located either in the main building or the east build-
ing of the participating hospital) was stated and justified
by the authors of the 17 primary studies. However, a clear
description of what was meant by traditional care or usual
Electronic search results Figure 2
Electronic search results. [see attached file 2] (PDF For-
mat).
Search product: 2386
Update search and 
citation tracking: 
261
Duplicates:
362 Embase, Cinahl
and Global Health: 
593
Cochrane register: 
302
Medline database: 
1592
Detailed search results
Table 3: Characteristics of studies included
Study-ID Study Quality Country Sample Size [N] Mean Age [Years] Diagnosis/Intervention
Invasive Care
Grines, CL 1998 Class I USA* 471 56 Primary Angioplasty in Myocardial Infarction
Swanson, CE 1998 Class II Australia 67 55 Femoral Fractures
Dowsey, MM 1999 Class II Australia 163 66 Hip and Knee Arthroplasty
Choong, PF 2000 Class II Australia 111 81 Fractured Neck of Femur
Aizawa, T 2002 Class II Japan 69 71 Transurethral Resection of the Prostate
Kiyama, T 2003 Class II Japan 85 63 Gastrectomy
Hirao, M 2005 Class II Japan 103 61 Gastrectomy
Non-Invasive Care
Falconer, JA 1993 Class II USA* 121 68 Stroke Rehabilitation
Gomez, MA 1996 Class I USA* 100 52 Myocardial Ischemia
Roberts, RR 1997 Class II USA* 165 48 Chest Pain
Johnson, KB 2000 Class II USA* 110 7 Paediatric Asthma
Kollef, HM 2000 Class II USA* 489 60 Respiratory Care
Marrie, TJ 2000 Class I USA* 19*** 64 Community-Acquired Pneumonia
Sulch, D 2000 Class II UK** 152 75 Stroke Rehabilitation
Kim, MH 2002 Class II USA* 18 48 Artrial Fibrillation
Chen, SH 2004 Class II Taiwan 42 8 Paediatric Asthma
Usui, K 2004 Class II Japan 61 48 Community-Acquired Pneumonia
Note: USA* = United States of America; UK** = United Kingdom; 19*** = (19) hospitals at random (1743 Patients)BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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care (control group) would have helped in assessing the
relevance of the study to other settings.
Primary studies reporting economic data, can be
described by a very limited scope of evaluation, focusing
on direct hospital LOS and costs effects, rather than on a
full economic evaluation [16]. In Table 3 the quality
assessment and characteristics of the 17 studies included
in the review and meta-analysis are shown in detail.
Effects on LOS
Out of the 16 studies (12 randomized and four non-ran-
domized studies representing a study population of 4,028
patients) examining the effect of clinical pathways on the
length of stay, 12 showed significant effects [23,24,26-
39]. However, heterogeneity between studies reporting on
LOS was substantial (I2 = 80%) and may refer to both the
statistical inconsistency as well as to the varying clinical
pathway interventions that were included. As a result, the
estimation of an overall pooled effect is not appropriate
and in Figure 3, the differences from the individual studies
in LOS are depicted together with the corresponding con-
fidence intervals without totals. The reported LOS in
Kiyama 2003 was calculated from the day of surgery to the
day of discharge [39]. All other studies included in this
analysis considered the total LOS.
Effects on patient outcomes
Out of 17 trials reporting effects on quality outcome
measures (see Table 1); six measures were comparable in
terms of re-hospitalisation and seven in terms of in-hospi-
tal complications [23-35,37-39]. In total, nine primary
studies were included in the Meta-analysis (representing a
study population of 1,674 patients), examining the effect
of clinical pathways on quality patient outcomes. The
pooled Odds Ratio (OR) for re-admission was 1.1 (95%
CI: 0.57 to 2.08) and for in-hospital complications the
overall OR was 0.7 (95% CI: 0.49 to 1.0). Statistical heter-
ogeneity was not present among the studies and there was
no evidence of difference in readmission to hospitals or
in-hospital complications. The effects of clinical pathways
on clinical outcomes in the individual studies are depicted
together with the pooled OR (see Figure 4 &5). There was
clinical variance in the range of follow-up periods that
were used by the investigators measuring re-hospitaliza-
tion (follow up periods ranged from 27 days to 6 month,
see Table 1) as well as the investigators used varying defi-
nitions of the term in-hospital complications (included
in-hospital complications were cardiac events, infections,
thrombosis, re-operation, sepsis and empyema). Obvi-
ously, this implies that any time element in the patient
outcome data is lost through this approach and it was not
possible to compute a series of dichotomous outcomes,
i.e. at least one event during the first year of follow up.
Effects on hospital costs
Six of the included studies (five randomized and one non-
randomized), representing a sample of 1328 treated
patients, reported on cost effects [26,28,31,33,34,39].
Four out of the five randomized studies found signifi-
cantly lower hospitalisation costs for pathway groups. The
statistical heterogeneity was substantial (I2 = 88%) and
compromised the estimation of a pooled effect. Addition-
ally, we also observed a considerable methodological var-
iation which refers to the different methods of cost
calculation used by the investigators. Some investigators
used a full cost approach (fix and variable costs included),
Effects on LOS Figure 3
Effects on LOS. [see attached file 3] (BMP Format).BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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whereas others calculated only direct hospital costs. Table
4 describes the costs differences in detail.
Subgroup analysis: invasive versus non-invasive clinical 
pathways
Five of the randomized studies, and two further non-ran-
domized studies assessed the LOS effects of surgical or
minimally invasive interventions [24,26,27,29,35,37,39].
The pooled effect for all invasive primary studies was -2.5
days (95% CI: -3.53 to -1.41). The differences in LOS in
the individual studies are depicted together with the total
effect per study type (RCTs versus CCTs, Figure 6). The sta-
tistical pooling of the subgroup of surgical pathway inter-
ventions is characterized by a considerable overall test-
value for statistical inconsistency (I2 = 60.9%) which also
reflects the clinical heterogeneity of the surgical pathway
interventions included in this comparison.
The subgroup of the conservative pathway indications
[23,28,30-34,36,38] had a reduction of LOS of approxi-
mately one day (WMD -0.75; 95% CI: -1.23 to -0.27, Fig-
ure 7).
Sensitivity analyses
The LOS effects were robust in terms of the sensitivity
analysis concerning the different statistical calculation
models (fixed versus random effects model) and the Year
of publication, adjusting for temporal trends. However,
we observed a trend toward greater reported LOS effects
from Japanese studies with a reduction of approximately
three days (WMD – 2.7), followed by studies carried out
in Australia (WMD – 1.5), Canada (WMD – 1.4) and the
USA (WMD – 0.8). Subsequently, we tested the hypothe-
ses, that different market forces (reported effect sizes per
country) are possibly confounding the conclusions of
these review and meta-analysis. After exclusion (stepwise/
Effects on in-hospital complications Figure 4
Effects on in-hospital complications. [see attached file 4] (BMP Format).
Effects on re-hospitalisation Figure 5
Effects on re-hospitalisation. [see attached file 5] (BMP Format).BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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iterative and all of the primary Japanese studies) of the
subgroup of Japanese studies, the (calculative) overall
LOS effect remained robust and statistically significant,
but tended to be smaller (WMD – 1.2; subgroup "Japa-
nese studies excluded" versus WMD – 1.5; subgroup "all
primary studies" included). This applies also to the sub-
group Analysis "Invasive versus non-invasive LOS effects",
after exclusion of the subgroup of Japanese studies (WMD
-0.6 conservative versus -2.2 invasive).
In addition, the overall odds ratios (OR) for re-admission
and in-hospital complications were robust in all terms of
the sensitivity analysis, indicating reliable pooled results.
Publication bias and other sources of systematic error
The funnel plot showed a relatively symmetric distribu-
tion (Figure 8), but the point cloud does not have a dis-
tinctive funnel form. The deficient funnel form of the
funnel plot can also be due to the relatively high hetero-
geneity with respect to the different pathway indications
of the primary studies included in these review (cross-
indicational methodology of the primary studies). Fur-
thermore, the number of studies was relatively small.
However, given that publication bias may still exist, the
statistical fail-safe N objectively helps to quantify. The cal-
culation about the number of file-drawer studies showed
that 101 non-significant studies would have to exist to
reduce the (calculative) overall effect size of (WMD) –
1.47 to a mean effect size of – 0.2. These results indicate
that unpublished research is unlikely to threaten the
validity of the original meta-analysis.
Secondary analyses
The graphic distribution of the original and the logarith-
mical (natural logarithm LN) LOS data clearly indicates
that there is a significant deviation from the normal distri-
bution (Figure 9a &9b). The heterogeneity between stud-
ies was not substantially lowered by the log
transformation.
The LOS reduction was estimated as 25 percent (95% CI:
-36% to -14%). For example, with the average length of
stay of 7 days, the estimated LOS effect was approximately
-1.7 days (7 days * -0.25 = -1.75 days LOS reduction). Fur-
Table 4: Cost data, standardized to the year 2000
Study ID Country Currency Experiment SD Control SD
Kiyama, T 2003 Japan US$ $14013 $2634 $18020 $7332
Kim, MH 2002 USA* US$ $879 $394 $1706 $1512
Kollef, HM 2000 USA* US$ $922 $1614 $1120 $1430
Grines, CL 1998 USA* US$ $11430 $6257 $13733 $7249
Roberts, RR 1997 USA* US$ $1877 $1243 $2574 $999
Gomez, MA 1996 USA* US$ $1535 $1985 $6768 $17359
Note: USA* = United States of America
Effects on LOS invasive pathways Figure 6
Effects on LOS invasive pathways. [see attached file 6] (BMP Format).BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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thermore, the pooled percentage LOS effects were similar
in fixed versus random effects models (WMD -0.25 versus
WMD -0.21).
Discussion
In general, the majority of studies reporting economic
data (LOS and hospital costs) showed a positive impact.
The results suggest that clinical pathways for invasive pro-
cedures generate clearer LOS effects (WMD -0.8 conserva-
tive versus -2.5 invasive).
Clinical pathways appeared to be effective in reducing
LOS and costs. Furthermore, pathways for invasive proce-
dures showed a stronger LOS reduction by comparing the
magnitudes of effect. These results may not be applied for
acute rehabilitation for stroke, where reverse effects were
reported (see effects on LOS, Figure 3) [23,38]. Both
trends were not statistically significant but they were in
contrast to the majority of pathway effects reported in the
present review. However, the question of comparability
may rise as a reflection of the differing pathway compo-
nents included in this review and also applies to the kind
and number of providers included in the primary studies.
We did not publish our review protocol prior to the study.
The review protocol for the follow-up study will be pub-
lished as a Cochrane review to prevent any doubt about
the comparison to be data-driven instead of protocol-
driven. We determined the scope of this review question
on a pilot analysis of existing primary study data resulting
in a diverse set of included studies. As it is an explanatory
analysis, the pooled results of the meta-analyses may only
apply for the majority of included pathway conditions
reporting positive effects or trends. Another limitation
refers to the poorly described control conditions reported
in the primary studies and implied both, the risk of con-
tamination, and the masking of effects. Therefore, we did
not pool the primary LOS and costs data from all of the 17
included studies and concentrated on examining the rela-
tionship between clinical subgroups (i.e. surgical versus
non-invasive pathway conditions).
It should be noted that the development and implemen-
tation of clinical pathways consumes a considerable
amount of resources. This corresponds to the fact that
truly achievable costs savings depend on the number of
cases (volume). This has to be included in the costs anal-
ysis. The inflation-adjusted costs for implementation
(without maintenance and further development) of the
pathway indication "Caesarian section" amounted to
nearly $20,000 [40]. However, since normally 20 percent
of the diagnoses cover 80 percent of the cases [18], a con-
siderable percentage of medical services can be dealt with
using a relatively small number of clinical pathways.
Therefore, the expenditures will amortize rapidly.
It is very important not to look too far into these results,
as there were some limitations. Moreover, it has to be
emphasised that evidence determined by meta-analysis is
always exploratory in nature and should be considered
with caution.
Due to the result of the relatively small number of studies
meeting inclusion criteria, this evidence base is not con-
Effects on LOS non-invasive pathways Figure 7
Effects on LOS non-invasive pathways. [see attached file 7] (BMP Format).BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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clusive enough to provide a replicable framework for all
pathway strategies. Considering the clinical areas for
implementation, clinical pathways seem to be effective
especially for invasive care. The likely benefits and costs
need to be considered by the local healthcare providers
when implementing clinical pathways under different cir-
cumstances. This review has shown that there is not one,
singular strong evidence base. Accordingly, decision-mak-
ers should also consider some limitations in relation to
the generalization of these findings. Replicating the
results of this review in other settings could be problem-
atic (e.g. ceiling effects such as market forces).
The heterogeneity in design and outcomes of the studies
was large and refers to the statistical heterogeneity in addi-
tion to the clinical variability of the included studies. This
precluded the overall pooling of LOS and cost data,
although the order of magnitude of effects indicated that
there are considerable implications of using clinical path-
ways.
It is unavoidable that some studies will have been over-
looked, despite our electronic search strategy. Studies
meeting our clinical pathway definition (see Table 1 &4)
were included, regardless of the fact that the term pathway
was mentioned in the study and was done to avoid subjec-
tivity. Also, studies were independently assessed and data
extracted by two with any disagreement discussed with a
third reviewer.
Finally, should be emphasised that the standard of the pri-
mary studies included pose a threat to the validity of the
results. While the overall quality of the included studies
was moderate, most demonstrated methodological weak-
nesses such as a small sample size available for analysis.
Conclusion
With respect to the totality of available evidence, the
knowledge about the mechanisms through which path-
ways work is insufficient. Future research should focus on
a better understanding of the key elements of clinical
pathways that have impact on economic and patient out-
Funnel plot analyses Figure 8
Funnel plot analyses. [see attached file 8] (BMP Format).BMC Health Services Research 2008, 8:265 http://www.biomedcentral.com/1472-6963/8/265
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comes. It is also surprising that more studies do not con-
sider any cost effects other than those of treatment.
Health-economic research should therefore concentrate
on costs of development and implementation of clinical
pathways.
This investigation is the first systematic review regarding
the effects of clinical pathways on process and patient out-
comes. We explicitly decided to expand this review and
will also include less restrictive study designs in addition
to randomized and quasi-randomized trials, to provide a
comprehensive theoretical basis. The character of non-
experimental studies makes them even more difficult to
critically assess and moreover, due to the lack of MeSH
terms the search results cannot be as sensitive as those for
purely RCT/CCT-based reviews. Another future direction
is a more comprehensive, patient-centered approach, con-
centrating more on patient-outcomes rather then health-
economic study endpoints. The next scheduled update for
this review is planned for the End of 2009.
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